As Pipeline Advances, Recursion Expands AI Focus to Clinical Trials

January 30, 2025 UCBN News, Syndication Comments Off on As Pipeline Advances, Recursion Expands AI Focus to Clinical Trials

Artificial intelligence (AI)-based drug developer Recursion Pharmaceuticals says it has begun a “ClinTech” effort that applies AI beyond drug design and discovery, toward the way it approaches clinical trials.

The post As Pipeline Advances, Recursion Expands AI Focus to Clinical Trials appeared first on GEN – Genetic Engineering…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Related Articles

News

Halia Therapeutics Reveals Promising Preclinical Obesity Data: HT-6184 and Semaglutide Combination Enhances Weight Loss and Preserves Lean Muscle Mass

September 23, 2024 UCBN News, Syndication Comments Off on Halia Therapeutics Reveals Promising Preclinical Obesity Data: HT-6184 and Semaglutide Combination Enhances Weight Loss and Preserves Lean Muscle Mass

LEHI, Utah, Sept. 23, 2024 /PRNewswire/ — Halia Therapeutics, Inc. (Halia), a clinical-stage biopharmaceutical company advancing novel therapies for inflammation-related diseases, today announced promising preclinical results from their investigational compound HT-6184, combined with the… Click […]

No Picture
News

Intermountain Health and PharmaLogic Partner to Develop and Expand Access to Novel Radiopharmaceuticals at New Salt Lake City Facility

March 4, 2024 UCBN News, Syndication Comments Off on Intermountain Health and PharmaLogic Partner to Develop and Expand Access to Novel Radiopharmaceuticals at New Salt Lake City Facility

MURRAY, Utah and BOCA RATON, Fla., March 4, 2024 /PRNewswire/ — Intermountain Health and PharmaLogic Holdings Corp. (“PharmaLogic”), a world-class contract development and manufacturing (CDMO) organization and radiopharmacy solutions provider, today announce a collaboration to […]